

AASOG 2024 Scientific Conference Program

Wednesday, August 14, 2024

Evening Welcome Reception, Revival Hotel

Thursday, August 15, 2024

8:15 am - Welcome by AASOG President, Alicia Gerke

Session 1: Teamwork Makes the Dreamwork: Sarcoidosis Multidisciplinary Teams

Confirmed Moderators: Ogi Obi and Brian Houston

- a. Introduction: "Starting with our Why"
Confirmed speaker: Nisha Gilotra
- b. Multidisciplinary: What does it mean in Sarcoidosis and how do we create it?
Confirmed speaker: Athol Wells (WASOG president)
- c. Training the Pipeline
Confirmed speaker: Laura Hinkle
- d. Mentoring the Next Generation
Confirmed panelists: Laura Koth, David Moller
Confirmed moderator: Michelle Sharp
- e. Therapeutics in a Multidisciplinary World
Confirmed speaker(s) - Barney Stern, Andrew Rosenbaum, Ennis James, Nadera Sweiss, Victoria Wotorson, Bryn Burkholder
- f. Panel Q&A

Coffee break

Session 2: Mind the Gap: Addressing Health Disparities

Confirmed Moderators: John Odakal and Wonder Drake

- a. Introduction: Overview of disparities in the field
Confirmed speaker: Michelle Sharp
- b. Gene-environment interactions and the relationship with socioeconomic factors
Confirmed Speaker: Yvette Cozier
- c. Improving disparities together (20 min)
Confirmed speaker: Logan Harper
- d. Translational implications: from bench to bedside to the real world
Confirmed speaker: Catherine Bonham
- e. Improving diversity in clinical trials
NHLBI Leadership

f. Panel discussion and Q&A

Lunch – Poster Viewing

Session 3:

Part 1: The Search for Precision in Sarcoidosis

Confirmed Moderators: Ed Chen and Nicholas Arger

- a. Overview of our current understanding of sarcoidosis pathobiology
Confirmed speaker: Ed Chen
- b. In vitro granuloma models and pathogen response
Confirmed speaker: Landon Locke
- c. Upper airway epithelial model and pathogen response
Confirmed speaker: Alejandro Pezzulo
- d. Advances in molecular studies of granulomas in tuberculosis (
Confirmed speaker: Erin F McCaffrey
- e. Role of TH17.1 cells and their interplay with macrophages in sarcoidosis
Confirmed speaker: Antje Prasse

Part 2: Is there an “Omics” definition of sarcoidosis? (80 min)

2:35-3:55pm

Confirmed Moderators: Skip Garcia, Daniela Cihakova, and Antje Prasse

- a. Exome and Snip/DNA
Confirmed speaker: Courtney Montgomery
- b. Transcriptomics
Confirmed speaker: Lisa Maier
- c. Epigenetics
Confirmed Speaker: Ivana Yang
- d. Proteomics
Confirmed speaker: Maneesh Bhargava
- e. Spatial Transcriptomics
Confirmed speaker: Jonas Schupp
- f. Panel (all Part 1 and 2 speakers): How do we integrate and work together to reach precision medicine?

Day 1 Wrap Up

Evening Event - AASOG Awards Dinner, Location TBD

Friday, August 16, 2024

7:30-8:15am Speed Mentoring Breakfast

Session 4: Outcomes in Sarcoidosis: To what end?

Confirmed Moderators: Arthur Yee, Jan Griffin

- a. What Outcomes Matter to Patients
Panel discussion from the Johns Hopkins Patient Advisory Board will give a patient perspective on outcomes that matter for patients.
Confirmed speaker(s) – Larry Franklin, Heidi Junk, Victor Eyo; Confirmed Moderator: Kayla Nyakinye

- b. Current state of clinical outcomes in multi-system sarcoidosis
Confirmed speaker: Dan Culver
- c. Health related quality of life and patient reported outcomes in sarcoidosis
Confirmed speaker: Lesley-Ann Saketkoo
- d. Development of Innovative Outcomes (20 min)
Confirmed speaker: Lisa Shulman
- e. Integration of Multidisciplinary Outcomes in Management and Research of Sarcoidosis: Panel Discussion and Q&A

Coffee break

Session 5: Clinical Trials: Something Old, Something New, Something Borrowed, Always Purple

Discuss clinical trials with a goal to highlight what clinical trials (or lack thereof) we have had in sarcoidosis and what lessons we have learned from our failures, successes, and challenges.

Invited Moderator: Elliott Crouser and Confirmed moderator: Jordana Kron

- a. Introduction: The importance of new treatment options in sarcoidosis
Confirmed Speaker: Carlos Pardo
- b. Clinical Trials: The journey so far and lessons learned
Confirmed Speaker: Leslie Cooper
- c. Borrowing from other multisystem diseases
Confirmed Speaker: Clifton Bingham
- d. FDA approach to outcomes in rare diseases
Confirmed speaker: FDA speaker
- e. Launching a Clinical Trial in Sarcoidosis
Confirmed speaker: David Birnie
- f. Pro/Con Debate: Clinical trials in sarcoidosis should be approached in a single organ specific manner
Confirmed speakers: Brian Houston (PRO) and Lisa Maier (CON)
- g. Panel Q&A

Lunch

Session 6: Addressing advanced disease in sarcoidosis: These sessions discuss some of the key clinical questions in management of “advanced sarcoidosis”, the forms of sarcoidosis with significant risk of loss of organ function or death. The sessions will take place as breakout sessions focused on advanced lung, cardiac and neurologic disease.

Breakout session A: Fibrotic sarcoidosis and sarcoidosis associated pulmonary hypertension

Advanced pulmonary fibrosis and sarcoidosis associated pulmonary hypertension contribute to high morbidity and mortality in sarcoidosis. There is a need to address individualized patient with respect to patient’s symptoms, comorbidities, assessment of inflammation and extent of fibrosis and its complications. The multifactorial and complex aspect of patients with advanced sarcoidosis related lung disease often require a multidisciplinary

discussion for optimal, personalized management. This session discusses the pathophysiologic basis of advanced pulmonary sarcoidosis, existing challenges, and treatment strategies.

Confirmed Moderators: Karen Patterson and Stephen Mathai

- a. Inflammation, fibrosis, and complications
Confirmed Speaker: Marc Judson
- b. Pro/Con Debate about anti-fibrotic use in management of pulmonary fibrosis in sarcoidosis
Confirmed speakers: Catherine Bonham & Karen Patterson
- c. Sarcoidosis associated pulmonary hypertension
Confirmed speaker: Oksana Shlobin
- d. Panel Q&A

Breakout session B: End stage pulmonary and cardiac disease

Sarcoidosis is an indication for lung and/or heart transplantation for end-stage disease, including fibrotic lung disease, heart failure or refractory arrhythmias. Despite these indications for transplantation, there are often delays in referral and challenges in management of these complex patients with systemic multiorgan disease. These challenges are in part related to a lack of specific transplantation guidelines for sarcoidosis. This session focuses on these knowledge gaps, highlighting recent data and approaches to transplantation in patients with advanced sarcoidosis.

Confirmed Moderators: Nisha Gilotra and Rohit Gupta

- a. Holistic approach to advanced pulmonary sarcoidosis and lung transplantation
Confirmed speaker: Rohit Gupta
- b. Advanced arrhythmia management in sarcoidosis
Confirmed speaker: Jordana Kron
- c. Advanced heart failure management in sarcoidosis
Confirmed speaker: Farooq Sheikh
- d. Panel Q&A

Breakout session C: Management of High Risk Neurosarcoidosis

Neurosarcoidosis is a high-risk disease form in patients with sarcoidosis. Sarcoidosis can involve any part of the nervous system and when it does, is difficult to treat. This session will discuss the various aspects of high risk neurosarcoidosis.

Confirmed Moderators: Jinny Tavee and Barney Stern

- a. Ocular neuropathy
Confirmed speaker: Amanda Henderson
- b. Hydrocephalus/Brain involvement
Confirmed Speaker: Jeff Gelfand
- c. Spinal Cord involvement
Confirmed speaker: Carlos Pardo
- d. Small fiber neuropathy, brain fog, and fatigue
Confirmed speaker: Paula Barreras
- e. Panel Q&A

Session 7: Abstract Presentations and Clinical Cases

- a. Oral abstract presentations
- b. Clinical case panel session: David Perlman, MD, University of Minnesota Medical School, Minneapolis, MN

Closing remarks - Chairs